Worth reading
53Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
67.9
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPNet Sales25,183Millions of yenYear on year +4.3%Progress 47.5%
Operating profit1,722Millions of yenYear on year +67.9%Progress 47.8%
Ordinary income1,753Millions of yenYear on year +66.7%Progress 47.4%
Net income attributable to owners of the parent1,034Millions of yenYear on year +57.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥51.28
Financial position at period-end
Total assets66,584Millions of yen
of which net assets 44,643 Millions of yenEquity ratio 67.0%vs. prior year-end +1.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+3,011
Investment-2,689
Financials-1,838
Net change-1,516
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period11,985 Millions of yen
Segment revenue
Medical Business12,20448.5%+1.4%
Tape business12,97951.5%+7.2%
Segment profit
Medical Business2,89169.0%-3.7%
Tape business1,29631.0%+258.7%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales53,000 Millions of yen (YoY +5.0%)
Operating profit3,600 Millions of yen (YoY +58.5%)
Ordinary income3,700 Millions of yen (YoY +51.5%)
Profit attributable to owners of the parent2,300 Millions of yen (YoY +39.2%)
Revision to Earnings ForecastNet Sales Not disclosed → 53,000 Millions of yen / Operating profit Not disclosed → 3,600 Millions of yen / Ordinary income Not disclosed → 3,700 Millions of yen / Profit attributable to owners of the parent Not disclosed → 2,300 Millions of yen
Annual Dividend Forecast40 Yen → 40 Yen（0.0%）
Factors Behind Changes in Business Performance
Revenue increased due to rush demand caused by supply concerns, the effects of price revisions, and other factors. Operating profit increased due to price revisions, the effects of productivity improvement initiatives at each production site, and other factors.
Disclosure regarding the going concern assumption
No applicable matters. The filing states, “There are no applicable matters.”
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidation0 additions and 0 exclusions (no company names)
Impairment loss35 Millions of yen
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Factory reorganization costs 230 Millions of yen, Costs of removing fixed assets (breakdown of plant restructuring costs) 194 Millions of yen, Impairment loss (breakdown of plant restructuring costs) 35 Millions of yen
Depreciation and amortization1,328 Millions of yen
Availability of Supplementary Financial Results MaterialsAvailable
Availability of Financial Results BriefingYes (for institutional investors)
Issued Shares at Period-End20,738,006 shares
Treasury Shares at Period-End557,097 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | 25,183 Millions of yen (YoY +4.3%) |
| Operating profit | 1,722 Millions of yen (YoY +67.9%) |
| Ordinary income | 1,753 Millions of yen (YoY +66.7%) |
| Profit attributable to owners of the parent | 1,034 Millions of yen (YoY +57.7%) |
| Net income per share | ¥51.28 |
| Equity ratio | End of the current fiscal period 67 / End of previous period 65.9 |
| Total assets | 66,584 Millions of yen |
| Net assets | 44,643 Millions of yen |
| Cash flows from operating activities | 3,011 Millions of yen |
| Cash flows from investing activities | -2,689 Millions of yen |
| Cash flows from financing activities | -1,838 Millions of yen |
| Cash and cash equivalents at end of period | 11,985 Millions of yen |
| Full-year earnings forecast | Net Sales 53,000 Millions of yen (YoY +5.0%) / Operating profit 3,600 Millions of yen (YoY +58.5%) / Ordinary income 3,700 Millions of yen (YoY +51.5%) / Profit attributable to owners of the parent 2,300 Millions of yen (YoY +39.2%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → 53,000 Millions of yen / Operating profit Not disclosed → 3,600 Millions of yen / Ordinary income Not disclosed → 3,700 Millions of yen / Profit attributable to owners of the parent Not disclosed → 2,300 Millions of yen |
| Annual Dividend Forecast | 40 Yen → 40 Yen（0.0%） |
| Segment revenue | Medical Business 12,204 Millions of yen (YoY +1.4%) / Tape business 12,979 Millions of yen (YoY +7.2%) |
| Segment profit | Medical Business 2,891 Millions of yen (YoY -3.7%) / Tape business 1,296 Millions of yen (YoY +258.7%) |
| Depreciation and amortization | 1,328 Millions of yen |
| Impairment loss | 35 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Factory reorganization costs 230 Millions of yen, Costs of removing fixed assets (breakdown of plant restructuring costs) 194 Millions of yen, Impairment loss (breakdown of plant restructuring costs) 35 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters. The filing states, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions and 0 exclusions (no company names) |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 20,738,006 shares |
| Treasury Shares at Period-End | 557,097 shares |
| Factors Behind Changes in Business Performance | Revenue increased due to rush demand caused by supply concerns, the effects of price revisions, and other factors. Operating profit increased due to price revisions, the effects of productivity improvement initiatives at each production site, and other factors. |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to rush demand caused by supply concerns amid the worsening situation in the Middle East, the effects of price revisions, and other factors. Operating profit increased due to price revisions, the effects of productivity improvement initiatives at each production site, and other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.